

890 West Pender Street, Suite 600
Vancouver, British Columbia
Canada V6C 1J9
778-998-5000



69 Longwood Avenue
Hyannis Port, MA, 02647 USA
617-571-6006
www.imaginmedical.com

CSE Symbol: IME
OTC Pink Symbol: IMEXF
Frankfurt/Stuttgart Stock Exchange: DPD2

NR-2017-IME - 23

Imagin Medical Announces Stock Options Granted

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company's initial focus is bladder cancer.

Vancouver, B.C. and Boston, MA, November 28, 2017 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced today that pursuant to the Company’s Stock Option Plan, an aggregate of 2,000,000 shares have been granted to certain directors, officers and consultants as incentive stock options at an exercise price of \$0.25 per share. The options are exercisable for a period of five years, ending on November 28, 2022.

About Imagin Medical

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com

For further information, contact:

Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: jhutchens@imaginmedical.com